162 related articles for article (PubMed ID: 26769844)
1. Metabonomic analysis of ovarian tumour cyst fluid by proton nuclear magnetic resonance spectroscopy.
Kyriakides M; Rama N; Sidhu J; Gabra H; Keun HC; El-Bahrawy M
Oncotarget; 2016 Feb; 7(6):7216-26. PubMed ID: 26769844
[TBL] [Abstract][Full Text] [Related]
2. MAL2 and tumor protein D52 (TPD52) are frequently overexpressed in ovarian carcinoma, but differentially associated with histological subtype and patient outcome.
Byrne JA; Maleki S; Hardy JR; Gloss BS; Murali R; Scurry JP; Fanayan S; Emmanuel C; Hacker NF; Sutherland RL; Defazio A; O'Brien PM
BMC Cancer; 2010 Sep; 10():497. PubMed ID: 20846453
[TBL] [Abstract][Full Text] [Related]
3. Differential expression of IL-8 and IL-8 receptors in benign, borderline and malignant ovarian epithelial tumours.
Browne A; Sriraksa R; Guney T; Rama N; Van Noorden S; Curry E; Gabra H; Stronach E; El-Bahrawy M
Cytokine; 2013 Oct; 64(1):413-21. PubMed ID: 23727325
[TBL] [Abstract][Full Text] [Related]
4. The O-Linked Glycome and Blood Group Antigens ABO on Mucin-Type Glycoproteins in Mucinous and Serous Epithelial Ovarian Tumors.
Vitiazeva V; Kattla JJ; Flowers SA; Lindén SK; Premaratne P; Weijdegård B; Sundfeldt K; Karlsson NG
PLoS One; 2015; 10(6):e0130197. PubMed ID: 26075384
[TBL] [Abstract][Full Text] [Related]
5. Pattern of tissue expression of CA-125 and HE4 in primary epithelial ovarian tumours and correlation with serum CA-125 levels.
Devan SM; Pailoor J; Sthaneshwar P; Narayanan V
Asian Pac J Cancer Prev; 2013; 14(8):4545-8. PubMed ID: 24083699
[TBL] [Abstract][Full Text] [Related]
6. MDM2 Expression in Serous and Mucinous Epithelial Tumours of the Ovary.
Abdelaal SE; Habib FM; El Din AA; Gabal SM; Hassan NS; Ibrahim NA
Asian Pac J Cancer Prev; 2016; 17(7):3295-300. PubMed ID: 27509966
[TBL] [Abstract][Full Text] [Related]
7. EphA8 is a prognostic marker for epithelial ovarian cancer.
Liu X; Xu Y; Jin Q; Wang W; Zhang S; Wang X; Zhang Y; Xu X; Huang J
Oncotarget; 2016 Apr; 7(15):20801-9. PubMed ID: 26989075
[TBL] [Abstract][Full Text] [Related]
8. Ovarian tumours of different histologic type and clinical stage induce similar changes in lipid metabolism.
Niemi RJ; Braicu EI; Kulbe H; Koistinen KM; Sehouli J; Puistola U; Mäenpää JU; Hilvo M
Br J Cancer; 2018 Oct; 119(7):847-854. PubMed ID: 30293997
[TBL] [Abstract][Full Text] [Related]
9. Assessment of the clinicopathological relevance of mesothelin level in plasma, peritoneal fluid, and tumor tissue of epithelial ovarian cancer patients.
Okła K; Surówka J; Frąszczak K; Czerwonka A; Kaławaj K; Wawruszak A; Kotarski J; Wertel I
Tumour Biol; 2018 Oct; 40(10):1010428318804937. PubMed ID: 30319054
[TBL] [Abstract][Full Text] [Related]
10. Weapons ovarian epithelial tumors may use in immune escape: an immunohistochemical correlational study.
Hasby EA
Pathol Oncol Res; 2012 Apr; 18(2):509-18. PubMed ID: 22161157
[TBL] [Abstract][Full Text] [Related]
11. Gene expression profiling of human ovarian tumours.
Biade S; Marinucci M; Schick J; Roberts D; Workman G; Sage EH; O'Dwyer PJ; Livolsi VA; Johnson SW
Br J Cancer; 2006 Oct; 95(8):1092-100. PubMed ID: 16969345
[TBL] [Abstract][Full Text] [Related]
12. The role and prognostic value of inducible nitric oxide synthase (iNOS) and interleukin-33 (IL-33) in serous and mucinous epithelial ovarian tumours.
Saied EM; El-Etreby NM
Ann Diagn Pathol; 2017 Apr; 27():62-68. PubMed ID: 28325363
[TBL] [Abstract][Full Text] [Related]
13. Gonadotropin (LH, FSH) levels in serum and cyst fluid in epithelial tumors of the ovary.
Chudecka-Głaz A; Rzepka-Górska I; Kosmowska B
Arch Gynecol Obstet; 2004 Nov; 270(3):151-6. PubMed ID: 12883823
[TBL] [Abstract][Full Text] [Related]
14. Calpain system protein expression and activity in ovarian cancer.
Zhang S; Deen S; Storr SJ; Chondrou PS; Nicholls H; Yao A; Rungsakaolert P; Martin SG
J Cancer Res Clin Oncol; 2019 Feb; 145(2):345-361. PubMed ID: 30448882
[TBL] [Abstract][Full Text] [Related]
15. Outcome in serous ovarian cancer is not associated with LATS expression.
Montavon C; Stricker GR; Schoetzau A; Heinzelmann-Schwarz V; Jacob F; Fedier A
J Cancer Res Clin Oncol; 2019 Nov; 145(11):2737-2749. PubMed ID: 31586262
[TBL] [Abstract][Full Text] [Related]
16. High-resolution proton nuclear magnetic resonance spectroscopy of ovarian cyst fluid.
Boss EA; Moolenaar SH; Massuger LF; Boonstra H; Engelke UF; de Jong JG; Wevers RA
NMR Biomed; 2000 Aug; 13(5):297-305. PubMed ID: 10960920
[TBL] [Abstract][Full Text] [Related]
17. Survivin expression and its correlation with cell proliferation and prognosis in epithelial ovarian tumors.
Sui L; Dong Y; Ohno M; Watanabe Y; Sugimoto K; Tokuda M
Int J Oncol; 2002 Aug; 21(2):315-20. PubMed ID: 12118327
[TBL] [Abstract][Full Text] [Related]
18. Expression and prognostic significance of the oncogenic K2P potassium channel KCNK9 (TASK-3) in ovarian carcinoma.
Innamaa A; Jackson L; Asher V; Van Shalkwyk G; Warren A; Hay D; Bali A; Sowter H; Khan R
Anticancer Res; 2013 Apr; 33(4):1401-8. PubMed ID: 23564779
[TBL] [Abstract][Full Text] [Related]
19. Prognostic impact of Dynamin related protein 1 (Drp1) in epithelial ovarian cancer.
Tsuyoshi H; Orisaka M; Fujita Y; Asare-Werehene M; Tsang BK; Yoshida Y
BMC Cancer; 2020 May; 20(1):467. PubMed ID: 32448194
[TBL] [Abstract][Full Text] [Related]
20. Claudin-4: a potential therapeutic target in chemotherapy-resistant ovarian cancer.
Yoshida H; Sumi T; Zhi X; Yasui T; Honda K; Ishiko O
Anticancer Res; 2011 Apr; 31(4):1271-7. PubMed ID: 21508375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
